多發性硬化症治療：全球藥劑市場 2012-2022 是由出版商Visiongain在2011年11月所出版的。
這份英文市場調查報告書包含116 Pages 價格從美金2642起跳。
本報告為，關注多發性硬化症治療藥物市場，並匯整全球及主要國家2022年止於本市場之10年間收益成長預測、目前主要產品及製藥商趨勢、控制症狀進展、防止復發等新藥開發現況之探討等最新調查資訊，以下列摘要形式闡述。
第1章 實施概要
- 多發性硬化症：治療市場概要
- 各章概要
- 調查及分析方式
第2章 多發性硬化症及治療簡介
- 多發性硬化症之病理
- 多發性硬化症之診斷
- 多發性硬化症之評估
- 各種多發性硬化症種類
- 復發性多發性硬化症
- 後續惡化型多發性硬化症
- 進展復發型多發性硬化症
- 初發惡化型多發性硬化症
- 其他多發性硬化症
- 多發性硬化症之因子
- 人口階層及地區分布
- 經濟成本
- 治療選項
- 症狀治療
- 發作治療
- 控制進展治療（緩和疾病治療）
- 其他藥劑、適應症外藥劑之治療
- 替代治療
第3章 全球多發性硬化症治療藥物市場 2011-2022
- 多發性硬化症市場 2010
- 2010年多發性硬化症市場之領導為Copaxone
- 干擾素構成半數以上市場
- 市場預測 2010-2022
第4章 主要國家之多發性硬化症治療藥物市場 2011-2022
- 主要國家之多發性硬化症治療藥物銷售及市場佔有率 2010
- 主要國家之多發性硬化症治療藥物市場：銷售預測 2011-2022
- 美國為多發性硬化症最大治療藥物市場
- 歐洲
- 德國：歐洲最大之多發性硬化症治療藥物市場
- 法國
- 西班牙
- 義大利
- 英國
- 日本
- 印度
- 中國
第5章 多發性硬化症治療藥物：銷售展望 2011-2022
- Copaxone
- 非專利藥物對Copaxone之競爭威脅
- Rebif
- Betaseron/Betaferon
- Tysabri
- Extavia
- Gilenya
- 生物仿製藥
第6章 多發性硬化症治療藥物之主要企業
- Biogen Idec
- Teva及Sanofi
- Novartis
- Merck Serono
- Bayer
第7章 舒緩疾病用R&D產品線
- 多發性硬化症治療藥物之產品線
- 迅速推進
- 現有藥劑之舒緩
- 調節免疫反應的藥物
- 消炎藥
- 促進髓鞘的藥物
- 疫苗治療
- 幹細胞治療
- Sativex
- 受矚目之多發性硬化症治療藥物產品線
第8章 多發性硬化症治療藥物產業及影響市場因素
第9章 訪問調查
- Dr Karen M. Stockl訪問（Prescription Solutions）
- Dr Johan Luthman訪問（Merck Serono）
- Dr Johan Luthman（Merck Serono）第2次訪問：幹細胞治療之遠景
第10章 本調查之結論
- 多發性硬化症市場雖持續成長，但範圍受限
- 主要市場中新產品及治療人口增加帶動持續成長
- 多發性硬化症中具有可行之治療藥物產品線
- 多發性硬化症治療藥物之主要企業
- 市場驅力
- 市場阻力
- 多發性硬化症治療藥物市場展望 - 結論
圖表一覽
Abstract
Report Details
What are the commercial prospects for multiple sclerosis treatment?
Visiongain's report shows you potential drug revenues to 2022. Find data,
forecasts and discussions.
Discover revenue predictions for multiple sclerosis (MS) treatments at world
market, product and national levels to 2022. Our report gives you business
research, analysis and data.
How will the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri,
Extavia and Gilenya perform to 2022? You can find potential revenues. Discover
information on disease-modifying agents for MS, the main focus of this work.
This study discusses Biogen Idec, Teva, Sanofi, Novartis, Merck Serono, Bayer
and other pharmaceutical companies. Receive information you need.
What does the future hold? With a strong R&D pipeline, the MS treatment sector
has potential to expand.
The market will change with the launch of new agents that slow symptom
progression and reduce relapse rates. Find R&D trends and commercial
opportunities there.
Visiongain's report provides data, analysis and opinion aiming to benefit your
research, calculations, meetings and presentations. You can find answers now
in our work.
Revenue forecasts, market shares, developmental trends, discussions and interviews
In our report you find revenue forecasts, growth rates, market shares,
qualitative analyses (incl. SWOT), an R&D review and opinions from our survey.
You receive 56 tables and charts and three research interviews.
Advantages of Multiple Sclerosis Treatment: World Drug Market 2012-2022 for your work
Our report gives you the following information and advantages:
- Find potential revenue to 2022 for the world MS drug market, viewing sales
growth
- Discover revenue forecasts to 2022 for leading MS drugs, assessing
commercial potential
- Assess leading companies, discovering their activities and prospects
- See revenue forecasts to 2022 for leading national markets - US, Japan,
UK, Germany, France, Spain, Italy, China and India
- Review R&D for treating MS, seeing pipeline trends
- Investigate competition and opportunities influencing the industry and its
sales
- Find out what will stimulate and restrain the industry and market
- View opinions from our survey, discovering research interviews.
There, you find a distinctive mix of quantitative and qualitative analyses
with independent predictions. We tackle crucial questions on MS treatment,
helping you to stay ahead.
Table of Contents
1. Executive Summary
- 1.1 Multiple Sclerosis: Treatment Market Overview
- 1.2 Chapter Breakdown
- 1.3 Research and Analysis Methods
2. Introduction to Multiple Sclerosis and its Treatment
- 2.1 The Pathology of Multiple Sclerosis
- 2.2 Diagnosis of MS
- 2.3 Measuring MS
- 2.4 The Different Types of Multiple Sclerosis
- 2.4.1 Relapsing Remitting MS
- 2.4.2 Secondary Progressive MS
- 2.4.3 Progressive Relapsing MS
- 2.4.4 Primary Progressive MS
- 2.4.5 Other Presentations of the Disease
- 2.5 Possible Causational Factors for MS
- 2.5.1 Genetic Factors
- 2.5.2 Infection
- 2.5.3 Environmental Factors and Less Well-Supported Theories
- 2.6 Demographics and Geographical Distribution
- 2.7 Economic Costs
- 2.8 Treatment Options
- 2.8.1 Treatment of Symptoms
- 2.8.2 Treatment of Attacks
- 2.8.3 Treatment of Disease Progression (Disease-Modifying Treatments)
- 2.8.4 Other Drugs and Off-Label Treatments
- 2.8.4.1 Rituxan (Rituximab, MabThera)
- 2.8.4.2 Campath (Alemtuzumab)
- 2.8.4.3 Novantrone (Mitoxantrone)
- 2.8.4.4 Imuran (Azothioprene)
- 2.8.4.5 Cyclophosphamide
- 2.8.4.6 Intravenous Immunoglobulin (IVIg)
- 2.8.4.7 Methotrexate (Maxtrex)
- 2.8.4.8 Low-Dose Naltrexone
- 2.8.5 Alternative Treatments
3. The World Market for MS Drugs, 2011-2022
- 3.1 The MS Market in 2010
- 3.2 Copaxone Led the MS Drug Market in 2010
- 3.3 Together, Interferons Form Over Half the Market
- 3.4 Market Forecast, 2010-2022
- 3.4.1 The Impact of New Drugs on the MS Market
- 3.4.2 The Impact of Generic Drugs on the MS Market
4. Leading National Markets for MS Drugs, 2011-2022
- 4.1 MS Drug Sales and Market Shares in Leading National Markets, 2010
- 4.2 Leading MS Markets: Sales Forecasts, 2011-2022
- 4.3 The US Is the Largest Market for MS Drugs
- 4.4 Europe
- 4.4.1 Germany Has the Largest EU Market for MS Drugs
- 4.4.2 France
- 4.4.3 Spain
- 4.4.4 Italy
- 4.4.5 The UK
- 4.5 Japan
- 4.6 India
- 4.7 China
5. Drugs for Treating MS: Sales Prospects, 2011-2022
- 5.1 Copaxone
- 5.1.1 Copaxone Sales Forecast 2011-2022
- 5.1.2 Copaxone Will Benefit from Label Extension
- 5.2 Threat from Generic Competition for Copaxone
- 5.3 Avonex
- 5.3.1 Method of Use Patent Extension to 2026
- 5.3.2 PEG-Avonex
- 5.4 Rebif
- 5.5 Betaseron/Betaferon
- 5.6 Tysabri
- 5.6.1 PML and the JCV Assay
- 5.7 Extavia
- 5.8 Gilenya
- 5.8.1 Quarter-on-Quarter Growth of Gilenya
- 5.9 Biosimilars
6. Leading Companies in the MS Drug Industry
- 6.1 Biogen Idec
- 6.1.1 Biogen Idec's Strong MS Pipeline
- 6.1.2 Biogen Has Licensed Ampyra, a Novel Treatment for MS Symptoms
- 6.1.3 The Threat of Biosimilars
- 6.2 Teva and Sanofi
- 6.2.1 Threats to Copaxone
- 6.2.1.1 Generic Competition for Copaxone
- 6.2.1.2 BG-12
- 6.2.1.3 Pipeline Copolymers
- 6.2.2 Opportunities for Copaxone
- 6.2.3 Extending Teva's MS Drug Franchise
- 6.3 Novartis
- 6.4 Merck Serono
- 6.5 Bayer
7. The R&D Pipeline for Disease-Modifying MS Treatment
- 7.1 MS Pipeline Drugs
- 7.2 Fast Forward
- 7.3 Modifications of Existing Drugs
- 7.3.1 PEG-INF (PEGylated Interferon Beta-1a)
- 7.3.2 NU100 (Interferon beta-1b) and NU400 (PEGylated Interferon Beta-1b)
- 7.3.3 Adjunct Therapies
- 7.4 Drugs that Regulate the Immune Response
- 7.4.1 Aubagio (Teriflunomide)
- 7.4.2 Laquinimod
- 7.4.3 Zanapax (Daclizumab)
- 7.4.4 Lemtrada/Campath (Alemtuzumab)
- 7.4.5 Oreclizumab
- 7.4.6 Trimesta
- 7.4.7 PI-2301
- 7.5 Anti-Inflammatory Drugs
- 7.5.1 BG-12 (Dimethyl Fumarate)
- 7.6 Drugs that Promote Remyelination
- 7.7 Vaccine Therapies
- 7.7.1 Tovaxin
- 7.7.2 BHT-3009
- 7.8 Stem Cell Treatment
- 7.9 Sativex
- 7.10 There is Strong Potential in the MS Drug Pipeline
8. Factors that Influence the MS Drug Industry and Market
- 8.1 SWOT Analysis
- 8.2 Market Drivers
- 8.2.1 The MS Market Has Opportunities for Continuing Growth
- 8.2.2 Labelling Extensions for New Indications Can Drive Uptake
- 8.2.3 Competition Between Older and Newer Products
- 8.2.4 Other Services
- 8.2.5 Drug Preference
- 8.2.6 Advances in Technology Will Benefit Patients and the Market
- 8.2.6.1 Targeting Patient Subpopulations
- 8.2.7 The Rise of Comparative Studies
- 8.3 Market Restraints
- 8.3.1 The Threat of Generics and Biosimilars (Follow-on Biologics)
- 8.3.2 Cost Concerns
- 8.3.3 Off-Label Use and Risk-Sharing Schemes
- 8.3.4 Side Effects and Treatment Compliance
9. Research Interviews
- 9.1 Interview with Dr Karen M. Stockl (Prescription Solutions)
- 9.1.1 Improving Self-Management of MS
- 9.1.2 The Impact and Benefits of DTM Programmes
- 9.1.3 Improving Medication Adherence in MS Patients
- 9.1.4 Impact of Oral MS Medications
- 9.2 Interview with Dr Johan Luthman (Merck Serono)
- 9.2.1 On Understanding the Disease and its Treatments
- 9.2.2 On Unmet Needs for Treatment
- 9.2.3 On Current Treatment Options
- 9.2.4 On Medical Marijuana Use
- 9.2.5 On Oral Drugs
- 9.2.6 On Future Treatment Possibilities
- 9.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically
Concerning Stem Cell Potential
- 9.3.1 On Stem Cell Media Coverage
- 9.3.2 On the Therapeutic and Curative Potential of Stem Cells for
Neurological Disorders
- 9.3.3 On the Treatment of Neurological Disorders
- 9.3.4 On Stem Cell Treatment of MS: Viability, Curative Power, Treatment
Strategy and Results
- 9.3.5 On the Time Frame for Marketable Stem Cell Treatment Options
10. Conclusions from the Study
- 10.1 Growth of the MS Market Will Continue, But Will Be Limited by
Competition
- 10.2 There Will Be Continued Growth in Leading Markets, Owing to New
Products and Expanding Treatment Populations
- 10.3 There is a Strong R&D Pipeline for MS Treatment
- 10.4 Leading Companies in the MS Drug Market
- 10.5 Market Drivers
- 10.6 Market Restraints
- 10.7 Prospects for the MS Drug Market - Concluding Thoughts
List of Tables
- Table 2.1 The Kurtzke Expanded Disability Scales (EDSS)
- Table 2.2 Multiple Sclerosis Populations and Prevalence for Leading
Countries, 2011
- Table 2.3 Licensed Disease Modifying Drugs for Multiple Sclerosis, 2011
- Table 3.1 Disease-Modifying Drug Sales, 2010
- Table 3.2 Sales of MS Drugs by Type, 2010
- Table 3.3 MS Drug Forecasts, 2010-2015
- Table 3.4 MS Drug Forecasts, 2016-2022
- Table 3.5 Current Leading Multiple Sclerosis Drugs: Forecast Revenues, 2022
- Table 4.1 Leading MS Markets by Country: Sales and Market Shares, 2010
- Table 4.2 Leading MS Markets: Revenue Forecasts by Country, 2010-2015
- Table 4.3 Leading MS Markets: Revenue Forecasts by Country, 2016-2022
- Table 4.4 US MS Drug Revenues, 2010-2022
- Table 4.5 German MS Drug Revenues, 2010-2022
- Table 4.6 French MS Drug Revenues, 2010-2022
- Table 4.7 Spanish MS Drug Revenues, 2010-2022
- Table 4.8 Italian MS Drug Revenues, 2010-2022
- Table 4.9 UK MS Drug Revenues, 2010-2022
- Table 4.10 Japanese MS Drug Revenues, 2010-2022
- Table 4.11 Indian MS Drug Revenues, 2010-2022
- Table 4.12 Chinese MS Drug Revenues, 2010-2022
- Table 5.1 Copaxone Revenues, 2010-2022
- Table 5.2 Avonex Revenues, 2010-2022
- Table 5.3 Rebif Revenues, 2010-2022
- Table 5.4 Betaseron/Betaferon Revenues, 2010-2022
- Table 5.5 Tysabri Revenues, 2010-2022
- Table 5.6 Extavia Revenues, 2010-2022
- Table 5.7 Gilenya Revenues, 2010-2022
- Table 6.1 MS Drugs and Their Producers, 2010
- Table 6.2 MS Drug Producers' Revenues, 2010
- Table 6.3 Biogen Idec Multiple Sclerosis Drug Pipeline, 2011
- Table 7.1 The Multiple Sclerosis Disease-Modifying Drug Pipeline, 2011
- Table 7.2 Preclinical Disease-Modifying Multiple Sclerosis Agents, 2011
- Table 8.1 SWOT Analysis of the MS Drug Industry and Market, 2011
- Table 8.2 Numbers of Medical MRI Scanners per 1,000,000 of Population for
Leading MS Treatment Markets
List of Figures
- Figure 3.1 Breakdown of the Multiple Sclerosis Market by Drug, 2010
- Figure 3.2 MS Drug Market Forecast, 2010-2022
- Figure 3.3 MS Drug Forecasts, 2010-2022
- Figure 3.4 MS Drug Revenues and Market Shares, 2022
- Figure 4.1 MS Drug Market Shares by Leading Country, 2010
- Figure 4.2 US MS Drug Revenues, 2010-2022
- Figure 4.3 German MS Drug Revenues, 2010-2022
- Figure 4.4 French MS Drug Revenues, 2010-2022
- Figure 4.5 Spanish MS Drug Revenues, 2010-2022
- Figure 4.6 Italian MS Drug Revenues, 2010-2022
- Figure 4.7 UK MS Drug Revenues, 2010-2022
- Figure 4.8 Japanese MS Drug Revenues, 2010-2022
- Figure 4.9 Indian MS Drug Revenues, 2010-2022
- Figure 4.10 Chinese MS Drug Revenues, 2010-2022
- Figure 5.1 Copaxone Revenues, 2010-2022
- Figure 5.2 Avonex Revenues, 2010-2022
- Figure 5.3 Rebif Revenues, 2010-2022
- Figure 5.4 Betaseron/Betaferon Revenues, 2010-2022
- Figure 5.5 Tysabri Revenues, 2010-2022
- Figure 5.6 Extavia Revenues, 2010-2022
- Figure 5.7 Gilenya Revenues, 2010-2022
- Figure 5.8 Gilenya Sales, Q4 2010-Q3 2011
多發性硬化症治療藥物市場預計2015年將達158億美金規模
2012年02月01日
Global Information, Inc.開始代理銷售由Visiongain所發行之報告「Multiple Sclerosis Treatment: World Drug Market 2012-2022 (多發性硬化症治療：全球藥劑市場 2012-2022)」。
Visiongain的報告中預測，緩和多發性硬化症（MS）用治療藥物於2015年將達到158億美金之規模。
MS藥物產業及市場於2015年止將持續擴大。特別是在美國、日本及英國等已確立且具有發展性的醫療市場上，其收益預估將有極大之成長。
MS治療市場將受到可延緩症狀進行、減少復發率之新藥劑上市帶動，而有所變化。
「將更具治療效果之方式導入MS藥物市場以及不需要注射之口服藥物等，勢必使接受治療之病患增加。」
Visiongain製藥產業分析師John O'Neil表示：「MS病患數多且治療可能獲得改善的英國市場，將會有極大之發展空間。」
本報告，將預測Copaxone、Avonex、Rebif、Betaseron/Betaferon、Tysabri、Extavia及Gilenya等治療藥物於2022年止之收益。
並提供Biogen Idec、Teva、Sanofi、Novartis、Merck Serono及Bayer等製藥公司之分析、多發性硬化症治療之R&D產品線評估、主要國家市場之預測等。
|
